That seems far too conservative.
a better approach is to determine the demand of a product and what clinical data has determined and determine if the product is good.
your approach would leave a lot of people buying a company overvalued. By the time a product is announced approved commercialisation you've lost all the upside.
look at beam therapeutics. Only a P1 asset, but already valued at 2.1b US. Obviously, a different market being Nasdaq, but application is similar.
That seems far too conservative.a better approach is to...
-
- There are more pages in this discussion • 2,741 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |